Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?

Ângelo Z. Mattos, Jose D. Debes, Arndt Vogel, Marco Arrese, Xavier Revelo, Tales Henrique S. Pase, Muriel Manica, Angelo A. Mattos

Research output: Contribution to journalReview articlepeer-review

Abstract

Hepatocellular carcinoma (HCC) is among the most common cancers and it is a major cause of cancer-related deaths. Non-alcoholic fatty liver disease (NAFLD) affects approximately one fourth of individuals worldwide and it is becoming one of the most important causes of HCC. The pathogenic mechanisms leading to NAFLD-related HCC are complex and not completely understood. However, metabolic, fibrogenic, oncogenic, inflammatory and immunological pathways seem to be involved. First-line therapy of advanced HCC has recently undergone major changes, since the combination of atezolizumab and bevacizumab was proven to increase survival when compared to sorafenib. Other immune-oncology drugs are also demonstrating promising results in patients with advanced HCC when compared to traditional systemic therapy. However, initial studies raised concerns that the advantages of immunotherapy might depend on the underlying liver disease, which seems to be particularly important in NAFLD-related HCC, as these tumors might not benefit from it. This article will review the mechanisms of NAFLD-related hepatocarcinogenesis, with an emphasis on its immune aspects, the efficacy of traditional systemic therapy for advanced NAFLD-related HCC, and the most recent data on the role of immunotherapy for this specific group of patients, showing that the management of this condition should be individualized and that a general recommendation cannot be made at this time.

Original languageEnglish (US)
Pages (from-to)3595-3607
Number of pages13
JournalWorld journal of gastroenterology
Volume28
Issue number28
DOIs
StatePublished - Jul 28 2022

Bibliographical note

Funding Information:
825510; Robert Wood Johnson Foundation, Harold Amos Medical Faculty Development Program to JDD; University of Minnesota Academic Investment Research Program–AIRP Grant to JDD; Fondo Nacional de Ciencia y Tecnología de Chilex to MA, No. FONDECYT-1191145; Agencia Nacional de Investigación y Desarrollo to MA, No. ANID-ACE 210009.

Funding Information:
Supported by European-Latin American ESCALON Consortium, Funded By The EU Horizon 2020 Program, No.

Funding Information:
Johnson Foundation, Harold Amos Medical Faculty Development Program, grants from Fondo Nacional de Ciencia y Tecnología de Chile and Comisión Nacional de Investigación, Ciencia y Tecnología , grants from University of Minnesota Academic Investment Research Program–AIRP grant, grants from Agencia Nacional de Investigación y Desarrollo (ANID ACE 210009), during the conduct of the study.

Publisher Copyright:
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Keywords

  • Hepatocarcinogenesis
  • Hepatocellular carcinoma
  • Immunology
  • Immunotherapy
  • Non-alcoholic fatty liver disease
  • Tyrosine kinase inhibitors

Fingerprint

Dive into the research topics of 'Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?'. Together they form a unique fingerprint.

Cite this